Last edition
News about "Novel Pan-Mutant PI3Ka Inhibitor ETX-636"
The investigational therapy targets activating PI3Ka mutations, which are found in up to 40% of hormone receptor-positive (HR+)/HER2-negative advanced breast cancers and are implicated in a variety of solid tumors.
Novel Pan-Mutant PI3Ka Inhibitor ETX-636 | 06/07/2025 | By Darshana | 235
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members